(GNOM) Global X Genomics & - Ratings and Ratios
Exchange: NASDAQ • Country: USA • Currency: USD • Type: Etf • ISIN: US37954Y4347 • Health
GNOM: Genomics, Biotechnology, Pharmaceuticals, Diagnostics, Research, Therapies
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, Genomics & Biotechnology Companies), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified. ‣ Company URL: ‣ Domicile:
Additional Sources for GNOM ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
GNOM ETF Overview
| Market Cap in USD | 68m |
| Category | Health |
| TER | 0.50% |
| IPO / Inception | 2019-04-05 |
GNOM ETF Ratings
| Growth 5y | -50.9% |
| Fundamental | - |
| Dividend | 1.0% |
| Rel. Strength Industry | -129 |
| Analysts | - |
| Fair Price Momentum | 8.63 USD |
| Fair Price DCF | - |
GNOM Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | % |
| Annual Growth 5y | -100.00% |
| Payout Consistency | 4.2% |
GNOM Growth Ratios
| Growth Correlation 3m | -59.4% |
| Growth Correlation 12m | -40.1% |
| Growth Correlation 5y | -81.3% |
| CAGR 5y | -7.39% |
| CAGR/Mean DD 5y | -0.19 |
| Sharpe Ratio 12m | -0.33 |
| Alpha | -37.61 |
| Beta | 1.11 |
| Volatility | 32.38% |
| Current Volume | 67.9k |
| Average Volume 20d | 74.2k |
What is the price of GNOM stocks?
As of January 23, 2025, the stock is trading at USD 10.18 with a total of 67,900 shares traded.
Over the past week, the price has changed by +5.35%, over one month by +2.62%, over three months by -5.74% and over the past year by -7.87%.
As of January 23, 2025, the stock is trading at USD 10.18 with a total of 67,900 shares traded.
Over the past week, the price has changed by +5.35%, over one month by +2.62%, over three months by -5.74% and over the past year by -7.87%.
Is Global X Genomics & a good stock to buy?
No, based on ValueRay Analyses, Global X Genomics & (NASDAQ:GNOM) is currently (January 2025) a stock to sell. It has a ValueRay Growth Rating of -50.89 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GNOM as of January 2025 is 8.63. This means that GNOM is currently overvalued and has a potential downside of -15.23%.
No, based on ValueRay Analyses, Global X Genomics & (NASDAQ:GNOM) is currently (January 2025) a stock to sell. It has a ValueRay Growth Rating of -50.89 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of GNOM as of January 2025 is 8.63. This means that GNOM is currently overvalued and has a potential downside of -15.23%.
Is GNOM a buy, sell or hold?
Global X Genomics & has no consensus analysts rating.
Global X Genomics & has no consensus analysts rating.
What are the forecast for GNOM stock price target?
According to ValueRays Forecast Model, GNOM Global X Genomics & will be worth about 9.6 in January 2026. The stock is currently trading at 10.18. This means that the stock has a potential downside of -5.3%.
According to ValueRays Forecast Model, GNOM Global X Genomics & will be worth about 9.6 in January 2026. The stock is currently trading at 10.18. This means that the stock has a potential downside of -5.3%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 9.6 | -5.3% |